

Minutes – Institutional Animal Care and Use Committee

University of Mississippi Medical Center

September 21, 2021

Time: 1:30 p.m.

Place: [REDACTED], WebEx

P	Chair/M8	V	19	V	M4	V	73
P	AV/28	V	M9*		48		M6
P	M1			V	52	V	82
V	5	P	M3	V	M5		
	M2	P	S1				20**
V	9					P	S2**

** [REDACTED] alternate for [REDACTED]
20 alternate for M5

Non-Voting Members:

	CSO	V	LR	V	Facility Manager		
	BSO	V	OHS	V	Facility Supervisor		
	RSO	V	VA RCO				

Due to COVID-19 members were given the option to join the meeting via WebEx. Designations:
P – in person; V – virtual via WebEx

Confirmation of quorum: 65%

I. OLD BUSINESS

VAMC: None

UMMC:

1. Semi-annual Report to the IO posted for member review in SharePoint.
 - a. Items identified during semi-annual for updating and retraining.
 - i. Documentation of personnel training: The OAW will send out training information to PIs.
 - ii. Rodent Survival Surgery Guidelines and surgical records: A subcommittee will review the Guidelines and provide recommendations next meeting. Subcommittee: M4/73
 - iii. Non-standard husbandry: Investigator will Feed/Water cards: The OAW has updated the training materials for the non-standard husbandry and will distribute to the research community.
 - iv. Use of heating pads: The CCR and OAW will develop guidelines to review at the next meeting.

II. NEW BUSINESS

VAMC: None

UMMC: None

A. Standing Program Reports:

1. Occupational Health and Safety: Representative from Student/Employee Health had no items to report.
2. Veterinary: The representative from CCR provided an update.
 - a. The CCR is half-way the current sentinel cycle.
 - b. Facility issue persist including:
 - i. HVAC in the [REDACTED] building. Replacement of unit is scheduled for 2022.
 - ii. Cage Washer in [REDACTED] building. The CCR is in the process of putting together a bid with expectation to go out in mid-October.
 - iii. The Assistant Director position is posted.
3. Legal: Representative from Legal has no items to report.
4. Training: No items to report.
5. Regulatory: OLAW and USDA annual reporting periods close September 30th. Annual reports are due by December 1.
6. Policy Statements and Guidelines: No updates.

B. Announcements/Other

1. The next scheduled IACUC meeting is October 19, 2021 and will be in person in CW308.
2. All New and Full Submission protocols will be submitted and reviewed in Cayuse.

C. Form update/revisions

III. MINUTES

1. August 17, 2021: Minutes were sent via email for review on August 26, 2021. The commenting period closed on September 2nd. Minutes accepted with minor updates. Accepted minutes have been posted in the SharePoint folder, Minutes Archives, and the VAMC minutes were sent via email.

IV. PROTOCOL

- A. Annual Continuation review:** Annual Continuation reports are reviewed and discussed at a convened meeting. Reviews were conducted prior to the September meeting and all reviews were accepted.
Reviewer: 73

VAMC: None

UMMC:

- a. 1567, Dr. 11
- b. 1568, Dr. 11
- c. 1436B, Dr. 33
- d. 1494A, Dr. 42
- e. 1493A, Dr. 67
- f. 1518A, Dr. 73 (reviewed by M8)
- g. 1305C, Dr. 74
- h. 1306C, Dr. 74
- i. 0932G, Dr. 83

B. Modifications

1. **Minor modification and Change in Personnel:** The following minor modifications and updates to personnel were approved since the August meeting.

VAMC: None

UMMC:

- a. Change in Personnel

- i. 1515A, 1568, 1583; Dr. 11
- ii. 1487A; Dr. 12
- iii. 1387B, 1388B, 1430B; Dr. 53
- iv. 1389B, 1512A; Dr. 58
- v. 1563; Dr. 63
- vi. 0486G, 1127D; Dr. 20
- vii. 1489A; Dr. 18
- viii. 1223D; Dr. 56
- ix. 1379B, 1547A; Dr. 5

2. **Significant Change VVC:** Summary of the modifications reviewed and approved by VVC since the August meeting was presented.

VAMC: None

UMMC:

1. 0878F, Dr. 2 (Mod 5), modify brief outline, update App C, and F Approved 9/3/21
2. 1245C, Dr. 36 (Mod 6), add experimental agent, update App F Approved 9/3/21

3. **DMR:** Summary of the modifications reviewed by DMR since the August meeting was presented.

VAMC: None

UMMC:

1. 1138D, Dr. 9 (Mod 3), addition of animals; modify brief outline
Reviewers: Primary – M5; Secondary – M3; Approved 8/24/21
2. 1574, Dr.84 (Mod 2), addition of animals, addition of experimental compounds; update App F
Reviewers: Primary – 52; Secondary – 5; Approved 8/26/21
3. 1475A, Dr. 12 (Mod 7), addition of animals , update App B
Reviewers: Primary – M4; Secondary – 9; Approved 9/10/21
4. 1585, Dr. 34 (Mod3), modify experimental outline
Reviewers: Primary – 9; Secondary – M3; Posted 9/2/21

4. **Major**

VAMC: None

UMMC:

1. 1541A, Dr. 47 (Mod 2), modify experimental outline, add hazardous agent
Reviewers: Primary – 5; Secondary – 19
The committee reviewed the modification and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional items were identified during discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

2. 1127D, Dr. 20 (Mod 8), addition of procedure
Reviewer: Primary – M8; Secondary – 5; **COI: M3 (out of room for discussion and vote), 73, 19 (off WebEx during discussion and vote)**
The committee reviewed the modification and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional items were identified during discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	11		Against:		Recused:	3
Quorum:	65%		Abstain:			

3. 1487A, Dr. 12 (Mod 2), addition of new strain

Reviewers: Primary – M3; Secondary – 9

The committee reviewed the modification and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional items were identified during discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

4. 1563, Dr. 63 (Mod 9), increase in animal numbers

Reviewers: Primary – M4; Secondary – 73

The committee reviewed the modification and discussed that no clarifications were needed.

A motion to approve the modification was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

Off-agenda items

5. 0932F, Dr. 83 (Mod 4), add breeding protocol

Reviewers: Primary – M8; Secondary – 28

COI: 82 (off WebEx for discussion and vote)

The committee reviewed the modification and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint, 2) clarify animal numbers, 3) clarify age of breeding.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	13		Against:		Recused:	1
Quorum:	76%		Abstain:			

6. 1565, Dr. 83 (Mod 5), add breeding protocol

Reviewers: Primary – M8; Secondary – 28

COI: 82 (off WebEx for discussion and vote)

The committee reviewed the modification and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint, 2) clarify animal numbers, 3) clarify age of breeding.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	13		Against:		Recused:	1
Quorum:	76%		Abstain:			

C. [New](#)

VAMC: None

UMMC:

1. *Perinatal inflammation, brain injury and neurodevelopment*

Dr. 19

Reviewers: Primary – M5; Secondary – M8; **COI: 19 (off the WebEx for the discussion and vote)**

Resubmission from July meeting

Pre-meeting communication was sent to the PI. The committee reviewed the protocol and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional clarifications were identified in the discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	13		Against:		Recused:	1
Quorum:	76%		Abstain:			

2. *POSS-femoral hemorrhage, a preliminary study*

Dr. 34

Reviewers: Primary – 82; Secondary – M4; **COI: 73 (off the WebEx for discussion and vote)**

No pre-meeting communication was sent to the PI. The committee reviewed the protocol and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint, 2) add endpoint information to #19A and change answer to #19B.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	13		Against:		Recused:	1
Quorum:	76%		Abstain:			

3. *Pathogenesis and therapy of bacterial pneumonia*

Dr. 40

Reviewers: Primary – 73; Secondary – 19

No pre-meeting communication was sent to the PI. The committee reviewed the protocol and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional clarifications were identified in the discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

4. *Endothelial glucose metabolism and Coronary microvascular dysfunction in aged female*

Dr. 94

Reviewers: Primary – M9 ; Secondary – 82

No pre-meeting communication was sent to the PI. The committee reviewed the protocol and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional clarifications were identified in the discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

D. 3-Yr. Full submission

VAMC: None

UMMC:

1. *Notch3 as a tumor suppressor in the postpartum mammary gland*

Dr. 81

For continuation approval must be in place by November 19, 2021

Reviewers: Primary – 52; Secondary – M9

No pre-meeting communication was sent to the PI. The committee reviewed the protocol and discussed that the PI needed to clarify: 1) Pre-meeting comments posted to SharePoint. No additional clarifications were identified in the discussion.

Following discussion, a motion that modifications were required to secure approval with designated member review following full committee review was passed by the following vote:

Vote For:	14		Against:		Recused:	
Quorum:	82%		Abstain:			

G. Protocols closed/set for closure:

VAMC: None

UMMC:

1. 0873G, Dr. 41; final report received
2. 1470A, Dr. 17; final report requested
3. 1244C, Dr. 75; final report requested
4. 1361B, Dr. 42; final report requested

The Chair called for other business; none was presented; the meeting adjourned at 2:38p.m.

Ending quorum: 82%

Prepared by: S1